安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Allogeneic T-cell Immunotherapy Company - Atara Biotherapeutics
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases
- Atara Biotherapeutics (ATRA)
Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory With cutting-edge science…
- T-cell immunotherapies for cancer, autoimmune . . . - Atara Biotherapeutics
Atara Biotherapeutics’s robust, late-stage pipeline features a host of potentially transformative T-cell immunotherapies for cancer, autoimmune and viral diseases
- T-Cell Immunotherapy Technology Platform - Atara Biotherapeutics
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases
- Technology - Atara Biotherapeutics
As a leading allogeneic T-cell immunotherapy company, Atara is pioneering the development of transformative therapies for patients with serious diseases by leveraging our novel allogeneic Epstein Barr virus (EBV) T-cell platform
- Atara Biotherapeutics Provides Regulatory and Business Update on . . .
About Atara Biotherapeutics, Inc Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory
- Press Releases :: Atara Biotherapeutics (ATRA)
Atara Biotherapeutics Announces U S FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
- ATRA Stock - Atara Biotherapeutics
Form 8937 - Organizational Actions Effective January 1, 2011, Internal Revenue Code Section 6045B requires issuers of corporate stock to provide information regarding corporate actions that affect stock basis Form 8937, Report of Organizational Actions Affecting Basis in Securities, is used to report such information FORM 8937: 6 20 2024 Reverse Stock Split
|
|
|